参考文献/References:
[1]Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.[2]Duma N,Santana-Davila R,Molina JR.Non-Small Cell Lung Cancer: Epidemiology,Screening, Diagnosis,and Treatment[J].Mayo Clin Proc,2019,94(8):1623-1640.[3]Jonna S,Subramaniam DS.Molecular diagnostics and targeted therapies in non-small cell lung cancer (NSCLC): an update[J].Discovery Medicine,2019,27(148):167-170.[4]Paz-Ares L,Socinski MA,Shahidi J,et al.Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase Ⅲ study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer[J].Annals of Oncology,2016,27(8):1573-1579.[5]Alexander M,Kim SY,Cheng H.Update 2020: Management of Non-Small Cell Lung Cancer[J].Lung,2020,198(6):897-907.[6]Kohno N,Inoue Y,Hamada H,et al.Difference in sero-diagnostic values among KL-6-associated mucins classified as cluster 9[J].Int J Cancer Suppl,1994,8:81-83.[7]Stahel RA,Gilks WR,Lehmann HP,et al.Third International Workshop on Lung Tumor and Differentiation Antigens: overview of the results of the central data analysis[J].Int J Cancer Suppl,1994,8:6-26.[8]Tomita M,Ayabe T,Chosa E,et al.Prognostic Significance of a Tumor Marker Index Based on Preoperative Serum Carcinoembryonic Antigen and Krebs von den Lungen-6 Levels in Non-Small Cell Lung Cancer[J].Asian Pac J Cancer Prev,2017,18(1):287-291.[9]Zheng M,Lou A,Zhang H,et al.Serum KL-6, CA19-9, CA125 and CEA are Diagnostic Biomarkers for Rheumatoid Arthritis-Associated Interstitial Lung Disease in the Chinese Population[J].Rheumatology and Therapy,2021,8(1):517-527.[10]Tomita M,Ayabe T,Chosa E,et al.Prognostic significance of preoperative serum Krebs von den Lungen-6 level in non-small cell lung cancer[J].General Thoracic and Cardiovascular surgery,2016,64(11):657-661.[11]Zhao J,Han Y,Li J,et al.Prognostic value of KRAS/TP53/PIK3CA in non-small cell lung cancer[J]. Oncology Letters,2019,17(3):3233-3240.[12]Schabath MB,Cote ML.Cancer Progress and Priorities: Lung Cancer[J].Cancer Epidemiology,Biomarkers & Prevention,2019,28(10):1563-1579.[13]Hirsch FR,Suda K,Wiens J,et al.New and emerging targeted treatments in advanced non-small-cell lung cancer[J].Lancet (London, England),2016,388(10048):1012-1024.[14]Arbour KC,Riely GJ.Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review[J].JAMA,2019,322(8):764-774.[15]Ramalingam SS,Owonikoko TK,Khuri FR.Lung cancer: New biological insights and recent therapeutic advances[J].CA: A Cancer Journal for Clinicians,2011,61(2):91-112.[16]Pao W,Girard N.New driver mutations in non-small-cell lung cancer[J].The Lancet Oncology,2011,12(2):175-180.[17]Korpanty GJ,Graham DM,Vincent MD,et al.Biomarkers That Currently Affect Clinical Practice in Lung Cancer:EGFR, ALK, MET, ROS-1, and KRAS[J].Frontiers in Oncology,2014,4:204.[18]Hirasawa Y,Kohno N,Yokoyama A,et al.KL-6, a human MUC1 mucin, is chemotactic for human fibroblasts[J].American Journal of Respiratory Cell and Molecular Biology,1997,17(4):501-507.[19]Hirasawa Y,Kohno N,Yokoyama A,et al.Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer[J].American Journal of Respiratory and Critical Care Medicine,2000,161(2 Pt 1):589-594.[20]Farahmand L,Merikhian P,Jalili N,et al.Significant Role of MUC1 in Development of Resistance to Currently Existing Anti-cancer Therapeutic Agents[J].Current Cancer Drug Targets,2018,18(8):737-748.[21]Sato S,Kato T,Abe K,et al.Pre-operative evaluation of circulating KL-6 levels as a biomarker for epithelial ovarian carcinoma and its correlation with tumor MUC1 expression[J].Oncology Letters,2017,14(1):776-786.[22]Namba M,Hattori N,Hamada H,et al.Anti-KL-6/MUC1 monoclonal antibody reverses resistance to trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity by capping MUC1[J].Cancer Letters,2019,442:31-39.[23]Kubo N,Araki K,Yamanaka T,et al.Perioperative management of hepatectomy in patients with interstitial pneumonia:a report of three cases and a literature review[J].Surgery Today,2017,47(10):1173-1179.[24]Horimasu Y,Ishikawa N,Tanaka S, et al.MUC1 in lung adenocarcinoma: cross-sectional genetic and serological study[J].BMC Cancer,2017,17(1):263.[25]Kumar S,Sharawat SK,Ali A,et al.Identification of differentially expressed circulating serum microRNA for the diagnosis and prognosis of Indian non-small cell lung cancer patients[J].Current Problems in Cancer,2020,44(4):100540.[26]Shoji F,Yamazaki K,Kouso H,et al.Predictive Impact for Postoperative Recurrence of Preoperative Serum Krebs von den Lungen-6 Concentration in Pathologic Stage IA Non-Small Cell Lung Cancer[J].The Annals of Thoracic Surgery,2016,101(5):1903-1908.[27]Tanaka S,Hattori N,Ishikawa N,et al.Krebs von den Lungen-6 (KL-6) is a prognostic biomarker in patients with surgically resected nonsmall cell lung cancer[J].International Journal of Cancer,2012,130(2):377-387.[28]Ogawa Y,Ishikawa T,Ikeda K,et al.Evaluation of serum KL-6, a mucin-like glycoprotein, as a tumor marker for breast cancer[J].Clinical Cancer Research,2000,6(10):4069-4072.[29]Xu H,Inagaki Y,Tang W,et al.Elevation of serum KL-6 mucin levels in patients with cholangiocarcinoma[J].Hepato-gastroenterology,2008,55(88):2000-2004.[30]Kimura T,Tanaka S,Haruma K,et al.Clinical significance of MUC1 and E-cadherin expression, cellular proliferation, and angiogenesis at the deepest invasive portion of colorectal cancer[J].International Journal of Oncology,2000,16(1):55-64.[31]Kurosaki M,Izumi N,Onuki Y,et al.Serum KL-6 as a novel tumor marker for hepatocellular carcinoma in hepatitis C virus infected patients[J].Hepatology Research,2005,33(3):250-257.[32]Yamasaki H,Ikeda S,Okajima M,et al.Expression and localization of MUC1, MUC2, MUC5AC and small intestinal mucin antigen in pancreatic tumors[J].International Journal of Oncology,2004,24(1):107-113.
相似文献/References:
[1]张秀芳,陈 萍.安罗替尼联合顺铂治疗晚期卵巢癌恶性腹腔积液的疗效观察[J].医学信息,2019,32(18):132.[doi:10.3969/j.issn.1006-1959.2019.18.044]
ZHANG Xiu-fang,CHEN Ping.Efficacy of Erlotinib Combined with Cisplatin in the Treatment of Advanced Ovarian Cancer with Malignant Ascites[J].Medical Information,2019,32(12):132.[doi:10.3969/j.issn.1006-1959.2019.18.044]
[2]厉 锋,鲍 乐,丁轶人,等.安罗替尼治疗晚期肝癌患者的效果[J].医学信息,2020,33(18):138.[doi:10.3969/j.issn.1006-1959.2020.18.045]
LI Feng,BAO Le,DING Yi-ren,et al.Anlotinib in the Treatment of Patients with Advanced Liver Cancer[J].Medical Information,2020,33(12):138.[doi:10.3969/j.issn.1006-1959.2020.18.045]
[3]王鹏飞,李崇慧.加味沙参麦冬汤联合安罗替尼治疗晚期非小细胞肺癌的临床观察[J].医学信息,2021,34(02):167.[doi:10.3969/j.issn.1006-1959.2021.02.047]
WANG Peng-fei,LI Chong-hui.Clinical Observation of Modified Shashen Maidong Decoction Combined with Anlotinib in the Treatment of Advanced Non-small Cell Lung Cancer[J].Medical Information,2021,34(12):167.[doi:10.3969/j.issn.1006-1959.2021.02.047]
[4]税 莲,邓海军,刘广国,等.卡培他滨联合安罗替尼三线治疗晚期非小细胞肺癌的安全性和有效性[J].医学信息,2024,37(21):30.[doi:10.3969/j.issn.1006-1959.2024.21.006]
SHUI Lian,DENG Haijun,LIU Guangguo,et al.Safety and Efficacy of Capecitabine Combined with Anlotinib in the Third-line Treatment of Advanced Non-small Cell Lung Cancer[J].Medical Information,2024,37(12):30.[doi:10.3969/j.issn.1006-1959.2024.21.006]
[5]阳 芳,黄 斌,覃超群,等.血清KL-6在安罗替尼治疗的非小细胞肺癌中的表达及临床意义[J].医学信息,2023,36(01):90.[doi:10.3969/j.issn.1006-1959.2023.01.017]
YANG Fang,HUANG Bin,QIN Chao-qun,et al.The Expression and Clinical Significance of Serum KL-6 in Non-small Cell Lung Cancer Treated with Anlotinib[J].Medical Information,2023,36(12):90.[doi:10.3969/j.issn.1006-1959.2023.01.017]